Audit Committee

1. The committee shall be composed of the entire number of independent directors. It shall not be fewer than three persons in number, one of whom shall be the convener, and at least one of whom shall have accounting or financial expertise.

   Members Background of the Audit Committee

Title / Name (Criteria)		Professional qualifications and experience	Independent Status	Number of other public companies concurrently serving as an independent director
Independent Director (convener)	Hsieh, Yin-Ching	Legal profession, operational judgements, international market perspective Working experience: 40 years	Please refer to statement of note	1
Independent Director (member)	Yang, Pan-Chyr	Biomedical Profession, business management, strategic planning Working experience: 46 years		1
Independent Director (member)	Ko, Fu-Hwa	Technology Profession, business management, industry knowledge Working experience: 40 years		0

The powers of the committee are as follows:

(1) The adoption of or amendments to the internal control system pursuant to Article 14-1 of the Securities and Exchange Act.

(2) Assessment of the effectiveness of the internal control system.

(3) The adoption or amendment, pursuant to Article 36-1 of the Securities and Exchange Act, of the procedures for handling financial or business activities of a material nature, such as acquisition or disposal of assets, derivatives trading, loaning of funds to others, and endorsements or guarantees for others.

(4) Matters in which a director is an interested party.

(5) Asset transactions or derivatives trading of a material nature.

(6) Loans of funds, endorsements, or provision of guarantees of a material nature.

(7) The offering, issuance, or private placement of equity-type securities.

(8) The hiring or dismissal of a certified public accountant, or their compensation.

(9) The appointment or discharge of a financial, accounting, or internal audit officer.

(10) Quarterly financial reports.

(11) Business reports and proposals for surplus distribution or loss offset.

(12) Other material matters of the Company or regulated by the competent authority.

2. The major annual review matters of 2025 Audit Committee were as follows:
   (1) Financial statements.
   (2) Internal control system.
   (3) Intercompany loans and endorsement and guarantee.
   (4) The audit plan and implementation of the internal audit unit.
   (5) Appointment, remuneration and independence assessment of the CPA.
   (6) Revising principles and regulations related to corporate governance.
3. There are 3 members of the Audit Committee.

4. The third term of office: 2024/05/30 to 2027/05/29.
   The third term Audit Committee held meeting 4 times in 2024. Attendance status of members is as follows:

Title	Name	Attendance in Person	Attendance by Proxy	Attendance Rate (%)	Remarks
Independent Director	Hsieh, Yin-Ching	4	0	100%	
Independent Director	Yang, Pan-Chyr	4	0	100%	
Independent Director	Ko, Fu-Hwa	3	1	75%	

   The third term Audit Committee held meeting 4 times in 2025. Attendance status of members is as follows:

Title	Name	Attendance in Person	Attendance by Proxy	Attendance Rate (%)	Remarks
Independent Director	Hsieh, Yin-Ching	4	0	100%	
Independent Director	Yang, Pan-Chyr	4	0	100%	
Independent Director	Ko, Fu-Hwa	4	0	100%	

5. Other disclosures:
   5.1 (1) Securities and Exchange Act §14-5 resolutions

Date	Resolutions	The Opinions of All Independent Directors and the Company's Actions to the Opinions
Feb. 23, 2023	1. 2022 financial statements and consolidated financial statements. 2. Fund loans between subsidiaries of the Company. 3. The Company's auditor of financial statements and audit Fee for 2023. 4. 2022 Statement of Internal Control System.	All independent directors approved
Apr. 19, 2023	1. 2023 Q1 consolidated financial statements.	All independent

Date	Resolutions	The Opinions of All Independent Directors and the Company's Actions to the Opinions
	2. The Company intends to loan funds to a subsidiary. 3. 2022 business report. 4. Distribution of 2022 Retained Earnings. 5. 2023 cash dividends distribution from retained earnings. 6. Cash distribution from capital surplus. 7. To establish the Company's " Rules Governing Financial and Business Matters Between the Company and its Related Parties". 8. Report on the situation of related party transactions in 2022. 9. Approval of related party transactions.	directors approved
Aug. 02, 2023	1. 2023 Q2 consolidated financial statements. 2. The Company intends to loan funds to a subsidiary. 3. The Company intends to endorse the guarantee for a subsidiary.	All independent directors approved
Oct. 19, 2023	1. 2023 Q3 consolidated financial statements. 2. Fund loans between the Company and its 100% invested companies. 3. Approval of the related party transactions for 2024. 4. 2024 annual audit plans 5. To amend the the Company's "Human Rights Policy (Including Human Rights Concerns and Practices)".	All independent directors approved
Feb. 26, 2024	1. 2023 financial statements and consolidated financial statements. 2. Report on the situation of related party transactions in 2023. 3. The Company and its 100% invested subsidiary provide loans to their subsidiary respectively. 4. The Company's auditor of financial statements and audit Fee for 2024. 5. The effectiveness of the Company's 2023 Internal Controls and Statement of Internal Control System.	All independent directors approved
Apr. 18, 2024	1. 2024 Q1 consolidated financial statements. 2. The Company intends to loan funds to a subsidiary. 3. Processing the renewal of a fund loan to a subsidiary. 4. 2023 Business Report. 5. Distribution of 2023 Retained Earnings. 6. 2023 cash dividends distribution from retained earnings. 7. Cash distribution from capital surplus.	All independent directors approved
May. 30, 2024	1. Election of the convener and chairman of the 3rd term audit committee. 2. Personnel changes of CEO and Deputy CEO of the Company.	All independent directors approved
Jul. 25, 2024	1. 2024 Q2 consolidated financial statements. 2. Purchasing an office in Taipei. 3. To amend the Company's "Audit Committee Charter". 4. To amend the Company's "Rules Governing Financial and Business Matters Between the Company and its Related Parties".	All independent directors approved

Date	Resolutions	The Opinions of All Independent Directors and the Company's Actions to the Opinions
	5. To amend the Company's "Risk Management Methods and Procedures".	
Oct. 29, 2024	1. 2024 Q3 consolidated financial statements. 2. The Company intends to extend the endorsement & guarantee period and adjust the endorsement & guarantee amount for a subsidiary. 3. The Company intends to loan a fund to a subsidiary. 4. Reporting transactions with the related party for 2025. 5. 2025 Annual Audit Plans. 6. To amend the Company's "Regulations Governing Procedure for Board of Directors Meetings". 7. To amend the Company's "Corporate Governance Best Practice Principles".	All independent directors approved
Dec. 13, 2024	1. To establish the Company's " Regulations on Realtek's Sustainability-related Information Management ".	All independent directors approved
Feb. 26, 2025	1. The Company's 2024 consolidated financial statements and parent company only financial statements. 2. The Company's business report for 2024. 3. The Company's distribution of 2024 retained earnings. 4. 2024 Cash dividends distribution from retained earnings. 5. Report on the situation of related party transactions in 2024. 6. The Company's auditor of financial statements and audit fee for 2025. 7. The Company's evaluation of the effectiveness of the internal control system for 2024 and statement of internal control system. 8. To amend the Company's Internal Control Systems. 9. Proposal for the issuance of 2025 new restricted employee shares.	All independent directors approved
Apr. 29, 2025	1. The Company's 2025 Q1 consolidated financial statements.	All independent directors approved
Jul. 31, 2025	1. The Company's 2025 Q2 consolidated financial statements. 2. To amend the Company's Issuance Rules of 2025 New Restricted Employee Shares. 3. The list of eligible recipients and number of shares for new restricted employee shares (excluding those who are directors or officers of the Company). 4. To amend the Company's Sustainable Development Best Practice Principles and Sustainability Information Management Procedure. 5. Proposal to terminate the balance of the intercompany loan between the Company's subsidiaries.	All independent directors approved
Oct. 28, 2025	1. The Company's 2025 Q3 consolidated financial statements.	All independent directors approved

Date	Resolutions	The Opinions of All Independent Directors and the Company's Actions to the Opinions
	2. The Company plans to lend funds to its subsidiary. 3. The intercompany loans between the Company's subsidiaries. 4. Report of transactions with the related party for 2026. 5. To amend the Personal Data Security and Maintenance Measures and rename to Privacy Policy. 6. To amend the Company's Risk Management Methods and Procedures. 7. To set the Company's risk appetite (risk tolerance) value at 15 (inclusive) or below. 8. The Company's annual audit plan for 2026.	

(2) The resolution which was not approved by the Audit Committee but was approved by two thirds or more of all Directors: None.

5.2 Execution of the independent directors' interests evasion: None.